Shares of Edwards Lifesciences Corp. EW, -1.14% rallied 3% in premarket trading Monday, after the company announced an agreement to sell its critical care product group to Becton Dickinson & Co. BDX, +2.29% in a cash deal valued at $4.2 billion. Edwards said it plans to use the proceeds from the sale to fund investments for growth, such as in technologies for technologies for aortic, mitral, tricuspid and pulmonic patients, and in therapeutic areas for interventional heart failure.
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE:BDX). The settlement provides for a fund of $85,000,000 to benefit class members.
The ProShares S&P 500 Dividend Aristocrats ETF hits its first speed bump in April, dropping by 4.69%. Some of this loss has been recovered in May. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 34 months of tracking these strategies, one strategy is outperforming NOBL, while 2 remain relatively close.
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE:BDX). The settlement provides for a fund of $85,000,000 to benefit class members.